All are designed to provide the benefit of high-quality nucleic acid material from which to run molecular testing and thereby qualify patients for targeted therapy drugs, using what would have been medical waste. For pharma companies sponsoring oncology therapy trials, this creates the opportunity to reduce attrition in the funnel of enrolled patients, because of more material from each biopsy, more data, and lower QNS rates.
About the Company
Corramedical's mission is to provide clinicians with the tools needed so that every solid tumor cancer patient has an opportunity to be treated with precision medicine -- oncologic therapy targeted to their tumor.
The company has a three-product line-up (one on the market and two in development), each designed to do this by making use of all the cellular resources extracted from biopsy patients: One for use after core needle biopsies, one after fine needle aspirate procedures, and one after solid tissue excisions.
Alexander Arrow, MD, CFA
Dr. Arrow co-founded Corramedical, Inc. in 2023 with Dr. Wilfrido Mojica. He has served in senior management roles or as a board member of medical device and biotechnology companies in the fields of interventional cardiology (Arstasis, Inc.), neuroscience (Circuit Therapeutics, Inc.), immuno-oncology (Neumedicines, Inc.), dentistry (Biolase, Inc.), otolaryngology (Zelegent, Inc.), hemostatic agents (Medcura, Inc.), neuro-active peptides (Protagenic Therapeutics, Inc.), spine surgery (Carlsmed, Inc.), solid organ transport (Paragonix Technologies Inc.), ophthalmology (Insightful Instruments, Inc.), and automation of drug discovery research tools (Strateos, Inc.).
He began his career as a surgical resident at the UCLA Medical Center, but left clinical practice in 1996 to become a sell-side equity research analyst covering medical technology. He switched careers a second time in 2007 when he left Wall Street to become the Chief Financial Officer of Johnson & Johnson – backed interventional cardiology start-up company Arstasis, Inc. During his five years as CFO the company grew from 30 to 120 employees and took a product concept through a multi-center clinical trial and into 140 U.S. hospitals. He has an MD from Harvard Medical School, and a BA in Biophysics, magna cum laude, from Cornell University.
Wilfrido Mojica, MD
Dr. Mojica, a practicing pathologist, co-founded Corramedical, Inc. in 2023 with Alexander Arrow. He is the chief of pathology at the Niagara Falls Memorial Medical Center, a community-based hospital that serves an inner-city population in Niagara Falls, NY. He is also an Associate Professor at the University at Buffalo (SUNY) in the Department of Pathology and Anatomical Sciences where he is involved in education of both medical and dental students. He has been interested and studied specimen procurement strategies from the surgical and interventional radiology perspective for years and has been developing methodologies to improve their recovery for testing once received in the pathology laboratory.
He has become an advocate to bring awareness to the presence of dislodged tumor cells in biopsy procedures, and in developing methods to save and utilize all the diagnostic cellular components that are often unkowningly available, but routinely not taken advantage of, so that high value outcomes can be derived to the benefit of the patient and cancer research. He has authored journal articles on this topic that have appeared in the American Journal of Interventional Radiology, the Journal of Clinical Pathology, and other peer-review publications. He seeks to change the current paradigm of suboptimal specimens being received in the pathology laboratory for testing to one characterized by the receipt of quality specimens in resulting in quality testing out. He has an MD from the St. Louis University School of Medicine, an M.S. in Physiology from Georgetown University, and a B.S. in Biological Sciences from the University of California, Irvine. He completed his pathology residency in Anatomic and Clinical Pathology at the State University of New York at Buffalo, and a Fellowship in Surgical Oncologic Pathology at the Roswell Park Cancer Institute.
Marco Thompson
Marco Thompson is a technology corporate executive and entrepreneur who has created, scaled, managed, and exited from multiple companies, in technology, software, and sporting equipment. In 1984 he founded his first company, Doctor Design, an embedded engineering services firm that contracted for AMD, Intel, Samsung, Mitsubishi, DIRECTV, Philips, Thomson, Sony, and IBM. He sold the $50 million firm to Integrated Systems, which merged with Wind River (WIND) in 2000, and then merged with Intel (INTC) in 2009. Stayed with the firm for 25 years before departing in November of 2009. He has served as Managing Partner at Express Ventures, an early-stage Venture Capital Firm, which has funded eight San Diego companies. He is the founder & Vice Chairman of San Diego Sport Innovators. He is the Vice-Chair of the Board of CONNECT, San Diego’s startup assistance organization. He was named the 2003 Alumni of the Year by the UCSD Jacobs School of Engineering and further honored by being inducted into the Hall of Fame for Engineering, Science and Technology. He joined the Corramedical Board of Directors in September 2024.
Shannon J. McCall, MD
Dr. McCall is an Associate Professor and the Vice Chair for Translational Research at the Department of Pathology of Duke University Medical Center. She is also the Director of the Duke Biospecimen Repository & Precision Pathology Center (Duke BRPC), a shared resource of the School of Medicine and the Duke Cancer Institute. She’s been a member of the Duke Cancer Institute since 2017. She is also the principal investigator (P.I.) for the National Cancer Institute's Cooperative Human Tissue Network Southern Division (12 states). Her areas of specialization include general gastroenterology, esophagus, stomach, colon, liver, and pancreatic tumors. Some of her published work contributed to the understanding of the unmet clinical need for the Corramedical Crow’s NestTM Biopsy Catchment System, in particular her seminal paper “Precision Pathology as Part of Precision Medicine: Are we Optimizing Patient’s Interests in Prioritizing Use of Limited Tissue Samples” Journal of Clinical Oncology Precision Oncology, 2019. She joined the Corramedical Scientific Advisory Board in January 2024.
David L. Waldman, MD, PhD, FSIR, FACR
Dr. Waldman is the editor-in-chief of the American Journal of Interventional Radiology, one of the preeminent peer-review journals of the field, and the editor of one of the fundamental textbooks of interventional radiology, Elsevier’s Interventional Radiology Secrets. He is Professor & Chief Medical IT development officer, Associate VP of the Department of Imaging Sciences at the University of Rochester Medical Center, in Rochester, New York. Under Dr. Waldman’s leadership as a world-renowned teacher, scholar, academician, and administrator, the Section of Interventional Radiology has grown into national prominence. He has been on the faculty in the Department of Imaging Sciences since 1994. He is a Fellow of the Society of Interventional Radiology and Fellow of the American College of Radiology. He is also a consultant for Brighton Surgical Center, Rochester, New York and has an adjunct Clinical Faculty appointment at Rochester Institute of Technology, Rochester, New York. Dr. Waldman received the Lifetime Service Award from the American Board of Radiology; and Distinguished Service Award from the American College of Radiology. He is a Board Examiner for the American Board of Radiology in Interventional Radiology. He joined the Corramedical Scientific Advisory Board in March 2024.
David B. Solit, MD
David B. Solit, MD is a practicing medical oncologist, a laboratory scientist, and the Geoffrey Beene Chair for Cancer Research at Memorial Sloan-Kettering Cancer Center (MSKCC) in New York, NY. As a member of the genitourinary oncology service, he specializes in the treatment of prostate and bladder cancers. He also serves as the director of the Marie-Josée & Henry R. Kravis Center for Molecular Oncology, and the Chief of MSKCC’s Molecular Medicine Service, in the Human Oncology & Pathogenesis Program. He leads a lab at MSKCC investigating when is it possible to inhibit an oncogenic pathway -- and thereby block tumor growth -- based on cell lineage and the specific mutations within the tumor.
Dr. Solit’s laboratory has been a leader in the development of selective inhibitors of the MAP kinase pathway, and defining mechanisms of resistance to RAF and MEK inhibitors. He pioneered the use of whole genome sequencing methods to identify occult predictors of drug response, work that serves as the basis for the NCI Extraordinary Responder Initiative. Via the Kravis Center for Molecular Oncology, Dr. Solit leads a multidisciplinary team of clinicians, geneticists, bioinformaticians and laboratory scientists whose mission is to integrate molecular and clinical information to develop therapies that are individualized to each patient’s cancer. He is a graduate of the University of Pennsylvania School of Medicine and completed a residency in Internal Medicine at Barnes-Jewish Hospital/Washington University in St. Louis. He joined the Corramedical Scientific Advisory Board in September 2024.
Maher Albitar, MD
Maher Albitar, MD, is the Chief Executive Officer, Chief Medical Officer, and Founder of Genomic Testing Cooperative, LCA. He has extensive experience in anatomic and clinical pathology, hematopathology, and molecular pathology. He was previously the Senior VP, Chief Medical Officer and Director of R&D at NeoGenomics. He is credited with transforming NeoGenomics from a FISH-only testing company to a company offering the most sophisticated molecular testing. Prior to NeoGenomics, Dr. Albitar served as the Medical Director for Hematopathology and Oncology, and Chief of R&D for Hematopathology and Oncology for Quest Diagnostics. Prior to leaving academia for industry, he was a tenured full professor at the University of Texas MD Anderson Cancer Center and served as Director of the molecular laboratory. Dr. Albitar has published more than 300 peer-reviewed papers, book chapters, and review articles. He is the lead inventor on more than 50 patents and patent applications. He joined the Corramedical Scientific Advisory Board in April 2025.
David R. Braxton, MD
Dr. Braxton is the Chief of Molecular Pathology Services at Hoag Memorial Hospital Presbyterian and the Hoag Family Cancer Institute in Newport Beach, California. He oversees the implementation of molecular diagnostic services and genomic profiling assays to guide personalized treatment strategies for cancer patients. He is known for advancing precision oncology initiatives at Hoag, one of the highest volume regional cancer centers in California. He is double-board certified in (1) Anatomic and Clinical Pathology, and (2) Molecular and Genetic Pathology. His clinical interests include the histological diagnosis of gastrointestinal, liver, and pancreatic disease as well as the application of molecular diagnostics in personalized medicine. He serves as Chair of the pathology working group, Precision Oncology Alliance, Caris Life Sciences. He joined the Corramedical Scientific Advisory Board in April 2024.
Mike Krietzinger
Mike Kreitzinger is the former head of clinical strategy and partnerships with Illumina, the market-leading manufacturer of genomic sequencers, a position he held for 10 years. Prior to that, he spent five years as head of sales of Alere, a diagnostics medical technology company that is now part of Abbott Labs. He was also part of the original sales team at Biosite, Inc., the company that some credit with pioneering point-of-care diagnostics as a medical device category.
Mike uses his extensive network of connections in the clinical laboratory space to raise awareness of the benefits to a lab to be able to offer molecular testing of the 5 mL liquid samples that Crow’s Nest customers will generate. His personal motto is: “Democratizing clinical genomics to improve healthcare in the genome era.” Mike joined as the Corramedical Market Outreach Advisory Board in March 2025.
Kenneth Pritzker, MD
Dr. Pritzker is a Professor Emeritus at the University of Toronto's Department of Laboratory Medicine and Pathobiology and Department of Surgery. From 1986 to 2008, Dr. Pritzker chaired the pathology and laboratory medicine department at Mount Sinai Hospital (MSH) in Toronto. His contributions to laboratory medicine, biomedical research, and hands-on experience implementing new diagnostic procedures have earned him recognition on a global scale. The laboratory at MSH rose to prominence as one of the world's leading organizations for cutting-edge lab services during his tenure there. As a companion diagnostic to colon cancer therapy, K-ras mutation testing, which today is considered standard-of-care, was introduced in Canada by Dr. Pritzker and his team.
Dr. Pritzker has pioneered writings on the implementation of cancer genomic and genetic tests. He serves as the CEO of SWAN Cytologics, and York Medtech Ventures, and as a Senior Advisor to Proteocyte Diagnostics, Inc., and RNA Diagnostics, Inc. Among his many peer-review publications, a review paper he wrote in 2019, Needle Biopsy Adequacy in the Era of Precision Medicine and Value-Based Health Care, Arch Pathol Lab Med. 2019;143:1399–1415 contributed to the inspiration for the mission of Corramedical, Inc. He joined the Corramedical Scientific Advisory Board in January 2024.
Daniel Gross, DNSc
Daniel Gross, DNSc, is a health care leader with 40 years of experience, predominately at Sharp HealthCare in San Diego, California, a renowned $5 billion not-for-profit healthcare system. Dr. Gross began his career at Sharp as a clinical nurse and rose through the ranks, serving as Chief Executive Officer of the Sharp Metropolitan Medical Campus for 11 years and ultimately becoming the health system Executive Vice President where he served for 14 years. His responsibilities as Executive Vice President included oversight of Sharp’s four acute care hospitals and three specialty hospitals, including its Clinical Effectiveness, Global Patient Services, Government Relations, Strategic Campus/Facility Development, and Physician Services.
Dr. Gross is a past member of the American Hospital Association Board of Trustees, California Hospital Association Board of Directors, Hospital Association of San Diego and Imperial Counties Board of Directors, California Health Care Foundation Board of Directors, American Heart Association/American Stroke Association Board of Directors, Trauma Care Association of America, San Diego Senior Community Board of Directors, and San Diego Chamber of Commerce. In addition, Dr. Gross serves as adjunct faculty for San Diego State University, University of San Diego, and University of California at San Diego.
Dr. Gross received his Bachelor of Science in Nursing degree from Wichita State University, his Master of Science in Nursing Administration from San Diego State University, and his Doctor of Nursing Science from University of San Diego. He joined the Corramedical Market Outreach Advisory Board in May 2025.
Shan Moledina
Shan Moledina has 18 years of leadership experience in launching novel diagnostics and advancing Clinical Lab 2.0 principles, emphasizing the central role clinical labs play in value-based oncology healthcare.
He has successfully driven the global commercialization of groundbreaking genetic, infectious disease, and oncology diagnostics. His experience spans Non-Invasive Prenatal Testing (NIPT) initiatives at Counsyl, launching molecular companion diagnostics (including Procalcitonin and BRAF mutation assays) at BioMérieux, and advancing molecular tumor profiling platforms at SOPHiA Genetics and PierianDx. Most recently before Corramedical, at Komodo Health, he was instrumental in leveraging healthcare data to track patient journeys and optimize clinical outcomes. At Corramedical, Shan spearheads the company’s efforts to increase the number of clinical genomics testing laboratories who accept liquid specimens generated by Crow’s Nest Biopsy Catchment System users, as well as major lab and other partnership initiatives.
Nathan Edwards
Nathan has an extensive Sales & Marketing background, with 25 years in sales positions in multiple non-medical industries. He has sold products as disparate as SaaS software, insurance, postage machines, payment processing systems, and now, medical devices. Since joining Corramedical, Nathan has been the voice that new prospective users of the Crow’s Nest often hear first. He is always ready to trouble-shoot and provide friendly and thorough customer service.
Jolly Desai
Jolly has over 12 years of experience in strategic financial and operational roles for SaaS, E-commerce, and Healthcare Technology companies. Her expertise includes financial planning, budgeting, forecasting, M&A due diligence (including the $10M acquisition of SeatAdvisor by Patron Technology, where she played a significant role on the leadership team), accounting process improvement, and performance initiatives. She spent nine years as Controller/HR Manager for SeatAdvisor and subsequently three years as VP Finance at Patron Technology. Previous roles include Controller at Optima Office and Formation Financial. Jolly holds a bachelor’s degree in accounting and a master’s degree in Art History. She is also the accountant for EvoNexus, the corporate incubator that houses Corramedical, Inc.
History of Biopsy Innovation
Pre-19th Century (Foundations)
Mid–Late 1800s
Early 1900s
Mid 20th Century
Late 20th Century
21st Century (Molecular Era)
- 1600s–1700s – Early physicians occasionally removed tissue for gross inspection, but without microscopy or standardized methods, it was rarely diagnostic.
__________________________________________________________________________________
Mid–Late 1800s
- 1858 – Rudolf Virchow publishes Cellular Pathology, proving that disease originates in cells and establishing the rationale for tissue examination.
- 1879 – Ernest Henri Besnier (France) coins the term “biopsie” to describe removing small living tissue samples for microscopic evaluation, especially in dermatology.
__________________________________________________________________________________
Early 1900s
- 1905 – Martin & Ellis describe the first systematic needle aspiration biopsies of solid tumors.
- 1930s – Martin & Stewart (New York Memorial Hospital) develop fine-needle aspiration (FNA) as a minimally invasive diagnostic technique.
- 1931 – Helmuth Johannes Riegler performs one of the first percutaneous liver biopsies.
__________________________________________________________________________________
Mid 20th Century
- 1950s–1960s – Widespread adoption of core-needle biopsy for breast, prostate, and other solid organs.
- 1960s – Image guidance emerges: fluoroscopy and ultrasound begin to assist percutaneous biopsies.
__________________________________________________________________________________
- 1970s–1980s – Computed Tomography (CT)-guided biopsy developed, allowing safe sampling of deep thoracic and abdominal lesions.
- 1990s – Vacuum-assisted breast biopsy devices introduced, reducing need for open surgical biopsy.
- 1990s–2000s – Widespread adoption of immunohistochemistry (IHC) on biopsy samples to guide targeted therapy.
__________________________________________________________________________________
- 2000s – Integration of molecular diagnostics (PCR, FISH) into routine biopsy workflows.
- 2010s – Next-generation sequencing (NGS) panels adopted in oncology, requiring optimized biopsy handling.
- 2010s–2020s – Liquid biopsy (ctDNA, CTCs, exosomes) introduced as a minimally invasive complement to tissue biopsy.
- 2020s – Tissue-stewardship strategies such as laser capture microdissection (LCM) and catchment systems like the Crow’s Nest™ address the problem of tissue exhaustion in molecular testing.
